78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion
Durham, NC, October 19, 2022 – BioAgilytix Labs, LLC (“BioAgilytix”), a leading bioanalytical laboratory focused on supporting pharmaceutical and biotech partners in all phases of drug development, has completed phase 1 of the latest expansion of its operations, with the opening of a 78,000 square foot building at 5927 South Miami Boulevard in Durham, North Carolina.
The construction of this new, state-of-the-art laboratory has tripled the current capacity for cell-based assays and high complexity flow cytometry to support immunogenicity, neutralizing antibodies, target engagement and biomarker assay design and validation, as well as sample testing in support of preclinical and clinical trials. A new dedicated cell culture suite with 3000 square feet is equipped to support complex high-volume large molecule bioanalysis.
The new site also boasts a spacious, custom-designed large molecule LCMS laboratory with state-of-the-art unit mass and high-resolution mass spectrometers to support drug discovery and development programs.
“BioAgilytix was founded in 2008 in a 7,600 square foot space that we have expanded to 89,000 square feet over the last 14 years. But without any further expansion options at that facility, it became necessary to expand capacity elsewhere in Durham,” said Linda Robbie, Chief Operating Officer of BioAgilytix. “This expansion enables us to keep pace with our customers’ ever-growing need for large molecule bioanalysis and supports our ability to hire and retain exceptional scientific talent who can meet our customers’ complex study requirements.”
“We are excited to continue the growth story of BioAgilytix. The ability to provide greater capacity and new service lines to our customers while maintaining the same high science, high quality delivery for every project is first and foremost on our mind,” said Jim McNally, Chief Scientific Officer of BioAgilytix. “The new space will allow us to continue to support drug development and accelerate their delivery to patients in need.”
BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across several industries and disease states.
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit bioagilytix.com.